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Maxim Moreau1,2, Bertrand Lussier1,3, Jean-Pierre Pelletier1 and Eric Troncy1,2*Abstract
A recent study investigated the therapeutic response of dogs afflicted by hip osteoarthritis when evaluating
therapeutic modalities compared to a negative (placebo) control group. Authors suggested a placebo effect based
on peak vertical force measurement. In addition, small effect size for each of the tested therapeutics as well as the
extremely large sample size needed (>450) to discern therapeutic efficacy using force platform gait analysis were
reported. We wish to express our concerns regarding the eligibility criteria used to select the studied cohort, the
small effect size, and the placebo effect reported in force platform gait analysis.
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cently published article on the clinical outcome mea-
sures in a randomized controlled trial (RCT) of canine
osteoarthritis (OA) from the perspective of clinical in-
vestigators. The article investigated the therapeutic re-
sponse of dogs afflicted by hip OA to three therapeutic
modalities compared to a negative (placebo) control
group [1]. The main goal of the study was to determine
the effect size (ES) of key outcome measures and, sec-
ondly, to highlight, in such RCTs assessing different
treatments, the interest of combining multiple (of differ-
ent nature) outcome measures. Effect size emphasises
the size of the difference rather than confounding this
with sample size as in statistical significance. However, it
is very rarely used in primary reports. Due to the un-
familiarity of using this test in such a context, we would
like to call for caution before a conclusion can be drawn
from this study.
As indicated in their Introduction, in a recent meta-
analysis of RCTs in human OA, Zhang et al. [2] reported
a placebo ES (the standard mean difference between* Correspondence: eric.troncy@umontreal.ca
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reproduction in any medium, provided the orbaseline and endpoint) of 0.51 (95% CI 0.46 to 0.55). Ef-
fect sizes can be interpreted in terms of the percentiles
or ranks at which two distributions overlap [3]. With an
ES of 0.51, the probability that one could guess which
group (naïve at baseline, or placebo at endpoint) a per-
son was in based on their ‘score’ is around 60%, whereas
an ES of 0.00 would logically provide a similar probabil-
ity of 50%. This is, at least in our judgement, a more
relative interpretation of a ‘mild’ ES (0.20 < ES < 0.80); a
placebo ES of 0.51 gives only a 10% increased chance of
determining the group of the examined person. Two
other points need to be reported from the study of
Zhang et al. [2]. They found placebo to be effective in
all subjective outcomes (not just patient-associated [e.g.
pain, stiffness, self-reported function] but also observer-
centred [doctor global opinion]), but ineffective for al-
most all objective outcomes (e.g. quadriceps strength,
knee circumference, range of movement, radiographic
narrowing); the ES of placebo was twice as high in hand
OA (0.80) compared to hip OA (0.37).
To reach their goal, Malek et al. [1] recruited dogs
having hip OA in addition to concomitant musculoskel-
etal conditions (n = 27/49, 55% of included dogs). Several
dogs (n = 7) had surgically altered hip or stifle joint
structures including excision arthroplasty and total hip
replacement. We believe that inclusion criteria should
have been more restrictive to homogenise the studiedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mechanical changes, thus preserving statistical power
and maximising ES. To avoid therapeutic plateau or
positive bias in outcome measures, which could be par-
ticularly harmful to the ES, we also believe in the necessity
of carefully defined wash-out periods for OA therapeutics
including joint supplements or diets (n = 24/49) purported
to improve afflicted dogs. Several peer-reviewed studies
published in the last few years have respected the imple-
mentation of wash-out periods for sporadic non-steroidal
anti-inflammatory drugs (NSAIDS), oral nutraceuticals,
OA therapeutic diets, fatty acid supplements, continuous
oral or injectable anti-inflammatory drugs (including both
steroids and NSAIDs), or polysulfated glycosaminoglycan
therapy [4-13].
Regarding the force platform gait analysis, the limb
with the smallest Fz vector (later referred to as peak ver-
tical force by Malek et al. [1]) was analysed, which does
not necessarily mean that this parameter departed from
normality. This was particularly critical considering the
large heterogeneity in the cohort of recruited dogs. One
would suggest, rather, a selection of subjects based on a
predetermined variable threshold [4,6,9,14]. This thresh-
old can be determined a priori with respect to normal
values [13]. We would also like to suggest a selection of
trials according to a velocity range limited to 0.3 m/s
(e.g. 1.6-1.9 or 1.9-2.2 m/s at the trot) [4,6-12,14] instead
of a larger one that overlaps walking and trotting gait in-
tervals (e.g. 1.3-1.9 m/s). For the measurement of pelvic
gait parameters, conditions that predispose dogs to thor-
acic limb pain or functional abnormalities, such as elbow
and shoulder OA, should be discarded to limit force redis-
tribution to the pelvic limbs [11]. Furthermore, no docu-
mentation of the body weight was recorded at the end of
the study. It is believed that this point is of importance as
changes in individual body weight can affect outcome
measures in OA dogs [15].
Is it unclear why Malek et al. [1] interpreted the changes
in falling slope observed in placebo-treated dogs as being
“an undesired effect” and “due to pain” (see Malek et al.
[1], Tables eight and eleven) when the authors later con-
cluded a placebo effect in dogs with hip OA after having
denoted a mean (standard deviation, SD) change in peak
vertical measurement of 2.8 (10.6)% body weight (see
Malek et al. [1], Table eight). Without precise information
on the stance phase duration, it is difficult to fully inte-
grate falling slope changes. As gait parameters are intim-
ately linked, it is strongly suggested to make a priori
determination of the primary outcome to avoid any mis-
leading interpretation.
We would like to express our disagreement with a sole
representation of force platform gait analysis data as
change in percentage relative to the initial condition. Ra-
ther, we suggest group central tendencies at each end-point as well as individual changes. Such representation
could have been useful to demonstrate the regression to
the mean phenomenon hypothesised by the authors [1]
in an attempt to support a placebo effect in dogs with
hip OA upon force platform gait analysis. Moreover, we
believe that the accumulation of previously listed meth-
odological short cuts could explain the large variability
in kinetic (force platform) parameters observed in the
study [1]. The variability of the results is reflected by the
large SD values in kinetic parameters reported in Malek
et al. [1], Table eight.
As mentioned by Malek et al. [1], dogs showing a
positive response to a negative control (placebo) were
previously observed based on peak vertical [6,16], but
globally the ground reaction forces did not demonstrate
clinically meaningful changes under placebo and rather
tend to be slightly negative [9,10,12,13]. This was con-
firmed by a recent meta-analysis including 40 OA dogs
followed over 28 days [mean (SD) change −1.5 (3.1)%
body weight with an intra-class coefficient of correlation
of 91, and only 5 dogs presenting a real positive re-
sponse for peak vertical force] [17] and a recent pro-
spective study including 58 OA dogs over 42 days [18].
These latter studies reported a rate of positive responses
around 10% using peak vertical force measurement.
Moreover, our concern about the negative interference
of the methodology used by Malek et al. [1] with the
kinetic measurement is supported by the absence of re-
sponse to carprofen, which could be considered a positive
control. Three previous publications reported positive re-
sponse on peak vertical force in n = 36, n = 15 and n = 16,
respectively, OA dogs treated with carprofen for 14 [16],
56 [13] and 60 [11] days. These findings could be related
to a high proportion of neuropathic dogs in the recruited
sample as mentioned by Malek et al. [1]. Hence, neuro-
pathic pain is recognized as non-responsive to NSAIDS
[19] and a component of a chronic painful condition such
as osteoarthritis in dogs [20,21]. It is unfortunate that
hyperalgesia/allodynia was not specifically tested in this
population of dogs with the use, for instance, of von Frey
anesthesiometer-induced paw withdrawal threshold, as re-
cently reported in OA cats [22].
We are in agreement with the clinical relevance of
reporting ES and the paramount importance of statistical
power and sample size estimates to design fruitful RCTs.
However, we encourage a thorough presentation of the
method used for single group ES calculation [23] from
which Malek et al. [1] derived their conclusions. The
interest of this publication remains in the original report
of a TRPV1 antagonist (ABT-116) and tramadol efficacy
in canine OA. However, the poor ES reported for each
of the tested therapeutics as well as the extremely large
sample size needed (>450) to discern efficacy of force plat-
form gait analysis, should be considered with scepticism.
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Force-plate analysis-of-gait is one of several different
outcome measures used in clinical trials studying client-
owned dogs with osteoarthritis. Approaches to experi-
mental design and statistical analysis of data in force-plate
analysis-of-gait studies vary widely in the veterinary litera-
ture and often vary from the perspective of Moreau et al.
For example, there are at least 10 different published
velocity ranges used for force-plate analysis-of-gait in
dogs, including a recent paper published in the Journal of
Veterinary Medical Association that used a velocity range
of 1.3-2.1 m/s [24].
The main objective of our study was to develop a
screening assay in client-owned dogs for analgesic activ-
ity of new compounds for the treatment of human and
veterinary osteoarthritis. As such, the number of animals
and the duration of the study were kept to a minimum.
Other studies have often used larger group sizes and
longer durations of treatment. In our study, effect size
determinations were used to establish which of the mea-
sured variables could best detect differences among
treatment groups. In undertaking a treatment experi-
ment, trial design may be restrictive or model-based,
such that a test article may show a treatment effect that
is subsequently less evident in clinical practice. Trials
that more closely model clinical practice represent a
greater treatment challenge for a test article to overcome.
Whilst homogenous cohorts are often used in experimen-
tal osteoarthritis studies, client-owned dogs represent a
more heterogeneous, but more clinically relevant, popula-
tion for longitudinal veterinary treatment studies. For
example, lumbosacral abnormalities in dogs are very
common and may not always have been identified in past
osteoarthritis studies in client-owned dogs. Lumbosacral
spondylosis is often an incidental finding in clinically nor-
mal dogs, but may also be associated with clinical signs.
Neuropathic pain as a clinical syndrome is poorly recog-
nized in dogs [19] and its association with lumbosacral
spondylosis is unclear. The responsiveness of dogs in the
present study to carprofen, as measured by the Canine
Brief Pain Inventory questionnaire [25], suggests that
neuropathic pain was not an important phenomenon in
our study.
Our study highlights the value of examining a combin-
ation of clinical outcome measures in clinically relevantlongitudinal studies of client-owned dogs with osteoarth-
ritis. Our study also highlights the need for better anal-
gesic treatments for canine osteoarthritis in veterinary
medicine. In this short-term study, habitual diet was
maintained to minimize change in body weight over
time. Whilst improvement in some gait analysis parame-
ters was identified with placebo treatment in our study,
these effects were not statistically significant. Some indi-
vidual dogs showed an improvement in measured pa-
rameters with carprofen treatment, similar to a previous
report, in which 19 of 34 dogs showed improvement in
ground reaction forces with placebo treatment [16].
To summarize, the article by Moreau et al. contributes
to discussion of force-plate analysis-of-gait as an outcome
measure in longitudinal studies in client-owned dogs with
osteoarthritis. Their commentary does not affect our
conclusions regarding its importance in small screen-
ing studies.
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